In addition, we demonstrated that SM treatment increased the levels of HO-1 and inhibited the ROS-induced IKKα signaling in the macrophages during inflammation in vitro and in vivo and, thus, might be beneficial for patients with CKD. The gene discussed is HMOX1; the disease is chronic kidney disease.